Patrick John Finn Sells 229 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total value of $10,440.11. Following the completion of the transaction, the chief operating officer now owns 274,466 shares in the company, valued at $12,512,904.94. The trade was a 0.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.

Twist Bioscience Price Performance

TWST opened at $45.62 on Wednesday. The company’s 50 day moving average price is $46.22 and its two-hundred day moving average price is $46.48. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -12.67 and a beta of 1.85. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Institutional Trading of Twist Bioscience

Several institutional investors have recently modified their holdings of TWST. Principal Financial Group Inc. lifted its holdings in Twist Bioscience by 210.2% during the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares during the period. Victory Capital Management Inc. boosted its holdings in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Arizona State Retirement System increased its position in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares during the period. Los Angeles Capital Management LLC raised its holdings in Twist Bioscience by 16.7% during the 2nd quarter. Los Angeles Capital Management LLC now owns 10,304 shares of the company’s stock worth $508,000 after purchasing an additional 1,475 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $556,000.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TWST shares. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird increased their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.